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A B S T R A C T   
Peripheral targets like pancreatic-lipase appear to be the most suitable pharmacological alternative for obesity, 
as with orlistat, although its adverse effects limit its use. Therefore, the aim of this work was to identify new 
natural compounds able to inhibit pancreatic-lipase in an in vitro model. The DrugBank database was used to 
perform docking calculations. The best fitting-score compounds were further evaluated in vitro. Our data revealed 
that glutathione-disulphide (GSSG) and silibinin(A) inhibit pancreatic-lipase. This was confirmed by measuring 
hydrolysis in an emulsion model, obtaining that the suppression of lipid digestion by silibinin(A) was higher than 
that of GSSG and close to the effect of orlistat. Combined analysis established the existence of different inhibition 
mechanisms for each compound. In summary, silibinin(A) and GSSG inhibited pancreatic-lipase and, therefore, 
may be served as promise natural compounds to face with obesity. Further studies comprise the next step to fully 
validate the suitability of these compounds.   
1. Introduction 
Although many factors are implied on obesity development, an 
excess of energy intake, especially in the form of dietary fat, and a 
sedentary lifestyle are still considered as the key factors for its devel-
opment (Heymsfield & Wadden, 2017). The problem of an excess of 
body fat is that those subjects are more exposed to the development of 
related diseases such as cardiovascular diseases and type 2-diabetes; 
therefore, apart from specific situations like the current COVID-19 
epidemic, obesity and its consequences are still the main cause of 
mortality in the world (Kass, Duggal, & Cingolani, 2020). Ultimately, a 
caloric intake greater than energy expenditure origins the accumulation 
of body fat and, consequently, obesity. As a result, the intake of high- 
palatable and high-fat food may prone subjects to increase their body 
fat (Gadde, Martin, Berthoud, & Heymsfield, 2018). Unfortunately, the 
food industry adds fatty acids in their commercial foods because it 
provides better organoleptic and tasted sensations for consumers 
(Zabetakis, 2013). 
At present, the gold therapy for obesity treatment is through modi-
fication of lifestyle habits, reducing energy intake through hypocaloric 
diets and increasing energy expenditure. Unfortunately, the effective-
ness of this intervention is quite modest, especially at the long-term. In 
several situations, in addition to conventional therapy, some drugs are 
administered to reduce caloric intake and to improve dietary treatment 
performance (Greenway et al., 2010). There are several FDA approved 
drug for obesity treatment: on the one hand, there are central-acting 
agents like lorcaserin, phentermine/topiramato, and naltrexone/ 
bupropion, which are useful but are usually related with several adverse 
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effects, including seizures, serotonin toxicity, mood disorders and even 
memory loss (Kim, 2016). On the other hand, peripheral-acting agents 
like Liraglutide or orlistat have been also evidenced as effective anti- 
obesity agents. Orlistat is the best-selling drug worldwide, and it is the 
unique drug allowed in adolescents for obesity treatment; its efficiency 
is similar to other drugs, but it is more secure since undesirable side 
effects are related to gastro-intestinal disorders like fecal urgency, fecal 
incontinence, flatus and oily spotting, which often leads to discontinu-
ation of therapy (Franson & Ro, 2000). It seems evident that the most 
suitable drug-therapy for obesity treatment might be through a similar 
mechanism to that of Orlistat, but with higher effectiveness and lower 
side-effects. In this regard, novel High-throughput screening techniques 
can allow us to find molecules that meet these characteristics. 
Nevertheless, to evaluate the effectiveness of potential inhibitors of 
pancreatic lipase, like orlistat, it is necessary to understand that the 
substrates of pancreatic lipase (such as long-chain triacylglycerols, 
tributyrin, etc) are water-insoluble molecules, while the pancreatic 
lipase is water soluble. In this way, the pancreatic lipase is adsorbed onto 
the oil–water interface of emulsion droplets to hydrolyse triacylglycerol 
into free fatty acids (FFA) and monoglycerides, which will be later 
absorbed in the small intestine (Wilde & Chu, 2011). Therefore, lipolysis 
occurs at the oil–water interface of emulsified substrates and as conse-
quence, the structure and composition of the interface is essential for 
pancreatic lipase activity (Li et al., 2018; Rahim, Takahashi, & Yamaki, 
2015). Inhibition of lipase action can be originated by adsorption, 
conformational changes, enzymatic processes and desorption of the 
lipolysis products. Potential lipase inhibitors with surface active prop-
erties could compete for the oil–water interface impeding lipase activity. 
(Delorme et al., 2011). Hence, the efficacy of potential lipase inhibitors 
and the specific events taking place at the interface ultimately can be 
rapidly assessed by monitoring changes in the interfacial tension of 
isolated interfaces (Del Castillo-Santaella et al., 2015), which allow 
quantifying the inhibition in a more realistic scenario (Maldonado- 
Valderrama, 2019). 
In this work, silibinin(A) and Glutathione-disulphide were selected 
by virtual screening and docking assays. Silibinin(A) is a flavonolignan 
extracted from milk thistle (Onopordum acanthium), which has been 
classically used for the treatment of fatty liver disorders (Singh, Gu, & 
Agarwal, 2008), while Glutathione-disulphide (GSSG) is the oxidized 
form of glutathione (GSH), an important natural antioxidant used as 
dietary supplement (Allen & Bradley, 2011). 
The objective of this study was first to screen, through virtual 
screening, a library of compounds as potential inhibitors of pancreatic 
lipase. In this regard, the docking studies revealed that silibinin(A) and 
GSSG could inhibit the pancreatic lipase. In the next step, the inhibition 
of pancreatic lipase was measured in different levels: in solution, at oil- 
water interface and in emulsion. The interfacial rapid assessment pre-
viously developed (Del Castillo-Santaella et al., 2015) was further vali-
dated through the quantification of the percentage of FFA upon lipolysis 
of an emulsion model, which confirmed the in silico outcomes. Com-
parison of different methodologies provided complementary informa-
tion allowing to establish the validity and limitations in order to obtain a 
valid model representative of the real situation. 
2. Material and methods 
2.1. Materials 
Lipase from porcine pancreas (Type II, 100–400 units/mg) protein 
purchased from Sigma-Aldrich® (cat n. L3126), stored at 4 ◦C following 
manufacturer’s instructions. Silibinin(A) was acquired from Sigma 
(S0417) and was stored at − 18̊C and L-Glutathione oxidized from Sigma 
(G4376) was stored at − 4̊C (Fig. 1). Tributyrin was purchased from 
Sigma-Aldrich® (W222305) and stored at room temperature. Highly 
refined olive oil (Sigma-Aldrich®, cat n. 01514) was purified with Flo-
risil® resins (Fluka, 60–10 mesh, cat n. 46385) prior to be used 
following the procedure previously described (Del Castillo-Santaella 
et al., 2015; Maldonado-Valderrama, Torcello-Gómez, Del Castillo- 
Santaella, Holgado-Terriza, & Cabrerizo-Vílchez, 2015). 
Titration buffer was prepared in 14.5 mL of TRIS-hydroxymethyl- 
aminomethane (36 mg/l), NaCl (9000 mg/l), CaCl2 (200 mg/l), So-
dium Taurodeoxycholate (2080 mg/l) and stored at 4 ◦C. Duodenal 
buffer was prepared in 2 mM BIS-TRIS (Sigma-Aldrich®, 14879), 0.15 M 
NaCl, 0.002 M CaCl2, pH 7.0, according to the standardized in vitro 
Fig. 1. The chemical structures of (a) Silibinin(A), (b) Glutathione-disulphide (GSSG), (c) Orlistat (Xenical®) and (d) Quercetin. ACD/ChemSketch software 
was used. 
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digestion method for food (Minekus et al., 2014). Lipase samples (7.8 g/ 
l) were prepared immediately before use in the duodenal buffer with Bile 
salts (5 mg/ml) for microbiology (Sigma-Aldrich®, B8756). Inhibitors 
were added to this mixture and filtered before use with Millex® filters 
(0.1 μm PDVF). 
Orlistat concentration was fixed at 0.44 mM in methanol (5.2% final 
concentrations). Silibinin(A) was dissolved in acetone and L-Glutathione 
oxidized was dissolved in duodenal buffer. Both inhibitors were tested at 
concentration 1.8 and 1.4 mM relevant to physiological studies (Del 
Castillo-Santaella et al., 2015). Lipase activity was measured with the 
same proportion of methanol or acetone as controls. 
Ultrapure water, cleaned using a Milli-Q water purification system 
(0.054 μS), was used for the preparation of buffer solutions. All glass-
ware was washed with 10% Micro-90 cleaning solution and exhaustively 
rinsed with tap water, isopropanol, deionized water, and ultrapure 
water in this sequence. All other chemicals used were of analytical 
grades and used as received. 
2.2. Virtual screening 
The first step to carry out this objective was the selection of an 
adequate compound database to conduct a virtual screening analysis. In 
this regard, the last release of DrugBank (version 5.1.4), which contains 
13,574 drug entries including 2632 approved small molecule drugs, 
1377 approved biologics (proteins, peptides, vaccines, and allergenics), 
131 nutraceuticals and over 6375 experimental (discovery-phase) drugs, 
was employed, allowing a comprehensive search for potential lipase 
inhibitor compounds, with the advantage that they have already been 
tested (or are being tested) in humans, so that potential hits could be 
used for use in humans more quickly (Wishart et al., 2017). More 
important, this database been used successfully for the repurposing of 
drugs orphan diseases (Govindaraj, Naderi, Singha, Lemoine, & Bry-
linski, 2018), which confirms the suitability of our procedure. 
All compounds deposited in DrugBank were set up for docking sim-
ulations by using AmberTools (AMBER 2017, University of California, 
San Francisco) (Case et al., 2017). Molecular parameters were calculated 
by removing salts and neutralizing their protonation state, computing 
partial charges by MMFF94 force field, adding hydrogen atoms and 
minimizing energies (default parameters) (Halgren, 1995). 
The crystal structure of pancreatic lipase (Protein Data Bank code 
1LPB) was used to build up the protein model system (Egloff et al., 
1995). At an early stage, bond orders were assigned, hydrogens were 
added, and cap termini were included with the Protein Preparation 
Wizard module as implemented in Maestro (Schrödinger Release 
2019–4: Maestro, Schrödinger, LLC, New York, USA) (Madhavi Sastry, 
Adzhigirey, Day, Annabhimoju, & Sherman, 2013). Protonation states of 
all side chains were subsequently defined using PROPKA3.1. Partial 
charges over all atoms were finally assigned within the AMBER99 force 
field scheme as implemented in AmberTools. Docking simulations were 
performed with Lead Finder software v1.1.20 (Stroganov, Novikov, 
Stroylov, Kulkov, & Chilov, 2008). All docking parameters were set to 
default for the calculations. The best ranked docking score posed for 
every compound was retained for further analysis. 
2.3. Pancreatic lipase activity 
2.3.1. The pHStat method 
This method was carried out to evaluate the pancreatic lipase activity 
using tributyrin as substrate and titration buffer. The free fatty acids 
released by the lipase were titrated at a constant pH 8.0 by sodium 
hydroxide (NaOH, 0.01 N) perfusion and 37 ◦C. 0.5 mL of tributyrin 
were mixed with the titration buffer described above (Carriere, Bar-
rowman, Verger, & René, 1993). Swine pancreatic lipase was also added 
at 50 μg. The inhibitors used in this method were: Orlistat (0.44 mM), 
GSSG (1.4 mM) and silibinin(A) (1.8 mM). 
The experiment is based on measuring lipase activity alone and in co- 
administration with the potential inhibitors and determining the volume 
of NaOH needed to maintain a constant pH 8.0, in each case. Then, the 







where, R (NaOH) represented the amount of µmol used per minute, 
which is equal to the amount of µmol of fatty acids released per minute. 
The volume (v) of enzyme was expressed in µL, having used 50 µL for all 
the assays, and [E] is the enzymatic concentration (mg in dry weight/ 
ml), which was 1 mg/ml. 
2.3.2. Emulsion formation 
Emulsions were formed by mixture of olive oil (1 g) with aqueous 
phase consisting of phosphate buffer (1.13 mM, pH 7.0) and 25% 
Tween-20 as model surfactant. First, the surfactant and buffer mixture 
was beaten in a Heidolph DIAX900 (potential 6, 1 min), and subse-
quently, the oil phase is added beating 5 for minutes more. A milky 
liquid is obtained, and this sample is sonicated in Branson Sonifier 450 
(Output control 10 and Duty Cycle 40%) in ice for 7 min in order to 
avoid the warming. The droplet size of the emulsions was measured after 
production in a DLS-Zeta-Sizer to assure the presence of monodisperse 
droplet distribution. The obtained droplet size was similar in all cases in 
order to eliminate effects from different surface area in the lipolysis 
(Torcello-Gómez, Maldonado-Valderrama, Martín-Rodríguez, & 
McClements, 2011). 
2.3.3. Pancreatic lipase-catalyzed hydrolysis of emulsions 
Determination of the pancreatic lipase activity by the pH-stat tech-
nique using olive oil from emulsion as substrate was carried out 
following the method described in (Torcello-Gómez et al., 2011). 3 mL 
emulsion were mixed with duodenal buffer to reach a final volume of 16 
mL and bile salts (5 mg/ml). For this method, lipase (1.6 mg/ml lipase) 
is added to start the measurement. The inhibitors tested were incubated 
with lipase for 15 min before addition: Orlistat (0.44 mM), GSSG (1.4 
mM) or silibinin(A) (1.8 mM). The free fatty acids released by the 
lipolysis of emulsions were titrated at a constant pH by sodium hy-
droxide (NaOH, 0.1 N) during the course of the hydrolysis. The titration 
is performed at 37 ◦C and at pH 7.0. 
The experiment is based on measuring the volume of NaOH needed 
to maintain the pH constant at 7.0, for lipase exclusively, and in the 
presence of its inhibitors. The % of free fatty acids produced in each case 







where, VNaOH is the volume of NaOH added, mNaOH is the molarity of 
NaOH, Mlipid is the molecular weight of lipid used, and Wlipid is the 
weight of lipid used, assuming that lipolysis produces two FFA per one 
triacylglicerol molecule. 
2.4. Analysis of in-vitro lipolysis in a single droplet 
The interfacial tension assays were made following the methodology 
and protocols described in detail in Del Castillo-Santaella et al. (2015). 
Interfacial tension is measured in a pendant drop surface film described 
in detail elsewhere (Maldonado-Valderrama et al., 2015). The system is 
completely computer controlled with Software DINATEN® (UGR) and 
the detection and calculation of surface area and surface tension are 
automatic and based on Axisymmetric Drop Shape Analysis (ADSA) 
(Cabrerizo-Vilchez & a, Wege, H. a, Holgado-Terriza, J. a, & Neumann, a 
W. , 1999). The solution droplet is formed at the tip of a capillary which 
is immersed in a glass cuvette filled with the oil phase (Hellma®), hence 
simulating an oil–water emulsion and is kept in an externally- 
thermostated cell at 37̊C for all the experiments. Interfacial tension 
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was recorded at constant interfacial area (20 mm2) and dilatational 
elasticity of the interfacial layer was measured at the end of adsorption 
curve at 5% amplitude and 0.1 Hz as described elsewhere (Del Castillo- 
Santaella, Sanmartín, Cabrerizo-Vílchez, Arboleya, & Maldonado- 
Valderrama, 2014, 2015). The adsorption curves and dilatational re-
sponses were recorded for lipase alone and in the presence of inhibitors 
as a rapid test of the inhibition of lipolysis induced by different com-
pounds following the methodology described in detail in (Del Castillo- 
Santaella et al., 2015). The inhibitors tested were incubated with 
lipase for 15 min before addition at the same concentrations as in pre-
vious assays: Orlistat (0.44 mM), 1.4 M and silibinin(A) (1.8 mM). 
2.5. Statistical analysis 
Pancreatic lipase activity data represent mean values ± standard 
deviations unless otherwise indicated. To estimate the total inhibitory 
effect of the tested compounds, AUC were estimated. Statistical differ-
ences regarding the effect of Xenical, GSSG and silibinin(A) were esti-
mated by a one-way ANOVA with a Tukey’s post hoc test for multiple 
comparisons, using SPSS 25 software (SPSS Inc., Chicago, Illinois, USA). 
Concentration-effect data for agonists and antagonists were fitted by 
nonlinear regression, fitting the data to a variable slope model, using 
Prism 8.0 software (GraphPAD, CA, USA). Data were pooled from at 
least three different samples. Statistical significance was set at p < 0.05. 
3. Results and discussion 
3.1. Search of potential inhibitors of pancreatic lipase active site 
Pancreatic lipase is a target of great interest for the pharmaceutical 
industry and, in consequence, many previous inhibitors have been 
developed for obesity treatment. This situation and the availability of an 
X-ray structure of pancreatic lipase allowed us to apply docking based 
Virtual Screening for the search of compounds that interact in a similar 
way as other compounds whose inhibitory capacity has already been 
demonstrated (Egloff et al., 1995). After performing virtual screening 
calculations, top 100 compounds with highest docking score were 
retained for further visual analysis and to check, if they interacted with 
the lipase key residues. Next, commercial availability of compounds was 
checked by Molport®, and finally we selected and purchased 
Glutathione-disulphide (GSSG) and silibinin(A) as main hits (Fig. 2), 
with docking scores − 12.2 and − 12.8 kcal/mol, respectively. In com-
parison, orlistat and tributyrin yielded − 11.1 and − 7.62 kcal/mol. 
Within the catalytic centre of pancreatic lipase, serine152 plays a 
pivotal role, since this residue forms a covalent bond with it with the sn- 
1 alkyl group necessary for the breakdown of the molecule (Egloff et al., 
1995). Our results showed that orlistat, GSSG and silibinin(A) were able 
to strongly bind to this residue, suggesting their potential activity as 
lipase inhibitors (Fig. 2). Very close to serine152, a leucine residue 
(leu153) helps to stabilize the protein-drug interaction. Interestingly, 
our virtual screening analysis revealed that orlistat and silibinin(A) (but 
not GSSG) formed a hydrogen-bond with this residue. Other important 
difference regarding the interaction of GSSG and silibinin(A) with 
pancreatic lipase relies on the his263 residue (Fig. 2), other member of 
the catalytic triad of pancreatic lipase (Lowe, 1992). Our data showed 
that both orlistat, tributyrin and GSSG interact through salt bridges with 
the imidazole ring of his263 from lipase, while these salt bridges were 
absent in the case of silibinin(A) Finally, other important regulator of the 
pancreatic lipase activity, Phe77, which showed several interactions 
with all four compounds (Fig. 2), but while orlistat, tributyrin and sili-
binin(A) were strongly linked to Phe77 through an interaction mediated 
by two hydrogen-bonds, GSSG interaction was weaker (a detailed 
description of protein–ligand interactions is available as supplementary 
Table S1). 
3.2. Inhibition of pancreatic lipase activity in solution 
Firstly, basal lipase activity in solution was determined as a negative 
control of the inhibition of lipase, so then, we could compare with the 
maximum activity of this enzyme. In the same line, orlistat was used as 
positive control. On this way, we established how many units of lipase 
could be inhibited using orlistat (Table 1), which was considered as 
maximum inhibitory effect. Secondly, the activity of lipase was 
measured in the presence of inhibitors GSSG and silibinin(A). 
Fig. 2. 3D representation of molecular docking results of Orlistat (a), Glutathione-disulphide (b), Silibinin(A) (c) and Tributyrin (d) with pancreatic lipase (Protein 
Data Bank: 1lpb). Hydrogen bonds are shown in red, hydrophobic interactions in purple, salt bridges in yellow and pi-stacking interaction in green. Relevant residues 
within the catalytic centre are shown as yellow thin sticks. Other residues interacting with the compounds are shown as orange lines. 
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Surprisingly, results in Table 1 show that only GSSG displayed a sig-
nificant inhibitory effect on lipase activity. Antioxidants are potential 
inhibitors of pancreatic lipase as demonstrated in literature studies (Li 
et al., 2018) and the reported inhibition is possibly associated with the 
antioxidant nature of GSSG (Surai, 2015). However, these authors use 
different methodologies to assess the inhibitory effects of lipase in so-
lution. In fact, according to this experimental protocol to assess lipase 
activity, orlistat and silibinin provided similar values to lipase (Table 1). 
A reason for this is the different solubility in water of the inhibitor in the 
reaction site, which importantly affects the direct measurement of lipase 
activity. Orlistat and silibinin(A), are practically insoluble compounds in 
water, while GSSG is completely soluble in water. This different solu-
bility could originate the different inhibitory activity found in solution. 
Orlistat is soluble in ethanol while silibinin (A) is soluble in acetone. The 
pancreatic lipase is inhibited clearly faster in the presence of GSSG 
owing to the high solubility of both compounds, which favours lipase 
inhibition, as measured in solution. However, this result is far away from 
the real situation during human digestion, where lipolysis occurs at 
oil–water interface of emulsified systems. Therefore, in order to obtain 
accurate and reliable information regarding lipolysis inhibition, it is 
important to develop more realistic models of lipase action, as it will be 
shown in the next section. Results shown in Table 1 will be just taken as 
fundamental information on the activity of compounds in solution, with 
no realistic applicability to the in vivo situation. 
3.3. Inhibition of pancreatic lipase activity at oil–water interfaces 
The inhibitory activity of silibinin(A) and GSSG on lipase action was 
evaluated using the rapid test based on interfacial tension measurements 
which was developed in a previous study (Del Castillo-Santaella et al., 
2015). The experiment designed therein consisted in measuring the 
adsorption profile of Lipase + Inhibitor and compare it to the adsorption 
profile of lipase and Lipase + Orlistat as negative and positive controls, 
respectively. All the measurements were carried out in an aqueous drop 
immersed in the oil phase mimicking oil–water emulsion and therefore, 
the physiological conditions of the duodenum. The interfacial tension 
decrease (obtained after 1 h of adsorption) depends on the adsorption of 
lipase and on the lipolysis products at the interface, so that, the lower the 
interfacial tension, the higher lipolysis occurred. The positive and 
negative controls were previously identified (Del Castillo-Santaella 
et al., 2015) being negative control: 5 mN/m (no inhibition of lipase 
enzyme at oil–water interface) and positive control: 9 mN/m (full in-
hibition of lipase at the oil–water interface). Then, the dilatational 
elasticity of the adsorbed layer provides additional information on the 
molecular conformation, composition and mode of inhibition. However, 
the complexity of this magnitude does not allow establishing positive 
and negative compounds as with the interfacial tension (Del Castillo- 
Santaella et al., 2015). 
With these premises, the interfacial tension and dilatational elastic-
ity were measured for the potential inhibitors proposed in this study, 
silibinin(A) and GSSG and compared to lipase and Lipase + Orlistat at 
fixed concentrations. Final values after 1 h of adsorption are plotted in 
Fig. 3. Figure Supplementary materials 2 shows the dynamic adsorption 
curves measured to reach the final state of Lipase + Silibinin(A) and 
Lipase + GSSG at the oil–water interface compared with the adsorption 
profiles of lipase and Lipase + Orlistat given in Fig. 3. 
On one hand, Fig. 3 shows no significant differences for Lipase +
Silibinin(A) as compared to negative control, both in the interfacial 
tension and the dilatational interfacial elasticity. This result is possibly 
also related to the lack of solubility of silibinin (A) in water. Solutions 
were made in acetone, which is also poorly soluble in water and 
therefore this methodology does not seem to be valid for assessing the 
inhibitory potential of silibinin(A). 
On the other hand, both, the interfacial tension and dilatational 
interfacial elasticity of Lipase + GSSG do provide significant differences 
with respect to positive and negative controls (Fig. 3). The obtained 
value for the interfacial tension suggests that lipolysis is inhibited in the 
presence of GSSG, but to a lesser extent than the inhibition reached with 
orlistat. The higher value compared to negative control suggest the 
lower amount of lipolysis products at the interface. The interfacial 
dilatational elasticity also lies in between that of negative and positive 
controls providing further information on the intermolecular and 
intramolecular interactions occurring within the interfacial layer (Mal-
donado-Valderrama, 2019). A lower dilatational elasticity implies the 
formation of a less cohesive network of lipase molecules owing to the 
presence of lipolysis products at the interface. The dilatational elasticity 
obtained for Lipase + GSSG appears significantly higher than that of 
negative control (lipase) meaning again that there has been a significant 
inhibition of lipolysis in the presence of GSSG. Orlistat is covalently but 
reversibly bound to the serine residue of the active site of lipase, but it 
does not seem to disrupt the lipase molecule (Bénarouche, Point, 
Carrière, & Cavalier, 2014). Accordingly, the high dilatational elasticity 
of Lipase + Orlistat might be originated from the compact structure of 
lipase, as discussed in detail in Del Castillo-Santaella et al. (2015). The 
lower dilatational elasticity of Lipase + GSSG could indicate that the 
inhibiting mechanism of GSSG produces a conformational change of 
lipase which could also explain the slight loss of elasticity of the inter-
facial layer. This is consistent with virtual screening data, showing that 
GSSG digs down towards the catalytic centre, hence altering the 
Table 1 
Average enzymatic activity value of lipase at 1 mg dry weight per minute. The mean value was calculated using sections between 2 and 8 min of each assay, where the 
highest catalytic activity was performed. Values are obtained as a mean of at least three replicate measurements.   
Lipase Lipase+Orlistat Lipase+GSSG Lipase+Silibinin(A) p (ANOVA) 
Enzymatic activity in dry weight U/(mg min) 30 ± 10 23 ± 10 15 ± 8* 24 ± 5 0.027 
Data represent mean ± standard deviation. Statistical differences were analysed by a one-way ANOVA. *Post hoc Tukey’s multiple comparisons test revealed sig-
nificant differences especially between GSSG and Lipase activity (p = 0.016). 
Fig. 3. Interfacial Tension and Interfacial dilatational elasticity obtained after 
1 h of adsorption at constant interfacial area onto the olive oil water interface in 
duodenal buffer. Lipase (blue), Lipase + Orlistat (red), Lipase + GSSG (purple) 
and Lipase + Silibinin(A) (green). Concentrations: Lipase (1.6 g/l), Orlistat 
(0.22 g/l), GSSG (0.88 g/l) or Silibinin(A) (0.88 g/l). Values plotted are mean 
values of three independent measurements and standard deviations are plotted 
as error bars according to statistical tool. Then, mean values were compared by 
using the Tukey’s test. Different letters were assigned at values with significant 
differences (p < 0.05). 
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conformational structure of lipase. 
3.4. Inhibition of in vitro lipolysis in a model emulsion 
In view of previous results, the inhibition of pancreatic lipase by 
silibinin(A) and GSSG was further analysed in a more realistic model by 
measuring the release of FFA from an oil–water emulsion stabilized with 
Tween20 in the absence or presence of inhibitors. This methodology 
allows measuring in vitro, the lipolysis of model emulsions under con-
ditions in the duodenum, being rather representative of the in vivo sit-
uation as recently shown (Deloid et al., 2018). 
Fig. 4 shows the influence of different inhibitors on lipolysis in model 
olive oil emulsions as measured using the pH method described in 
Section 2.3.3. The rate and extent of FFA release decreased in the 
following order: Lipase > Lipase + GSSG > Lipase + Silibinin > Lipase 
+ Orlistat (Fig. 4). The suppression of lipid digestion by silibinin(A) is 
therefore more significant than that of GSSG and importantly 
approaching that of orlistat. Regarding the solubility of silibinin(A), it 
seems to be improved by emulsification; the higher energy introduced in 
the system by agitation and sonication of the sample, the presence of 
emulsifier and bile salts and also the partial solubilisation in the oil 
phase could be responsible for the improved solubility reached. At any 
rate, results from Fig. 4 allow evaluating the inhibitory potential of 
silibinin(A) and also, confirm its high inhibitory potential. 
Fig. 4 also quantifies the activity of lipase and Lipase + Inhibitor in 
olive oil emulsion. The presence of orlistat decreases in the activity of 
lipase by 71% and a similar inhibition was obtained with Lipase- 
Silibinin(A) (65%) in contrast to GSSG which shows a 46% inhibition 
of pancreatic lipase activity (Fig. 4). The inhibition can be further ana-
lysed by looking at the lag time and linear lipolysis rate (Chu et al., 
2009). The lag time is defined as the time in minutes taken before 
lipolysis (Supplementary Table 2). This lag time followed the trend: 
lipase-orlistat > lipase-silibinin> lipase-GSSG> lipase. The maximum 
linear lipolysis rate can also be measured (g of consumed olive oil/min) 
obtaining lipase > lipase-silibinin(A) > lipase-orlistat > lipase-GSSG 
(Supplementary Table 2). The statistical studies showed similar rate 
for lipase-silibinin and lipase-orlistat and lipase-GSSG and lipase-orlistat 
(Supplementary Table 2). This agrees with results from Chu et al. who 
obtained similarly that the system which had less lipolytic activity 
presented a lag time 17.53 ± 0.51 min and maximum rate minor than 
the other systems (Chu et al., 2009). 
These results allow extending and interpreting previous findings to 
more realistic conditions and also linking with structural aspects. 
Experimental results demonstrate that both inhibitors are promising 
agents in the development of natural compounds to reduce fat intake. 
However, the inhibitory effect of silibinin(A) seems more pronounced, 
than that of GSSG even approaching that of orlistat. The improved 
performance of silibinin(A) could be related to its improved interaction 
with hydrophobic sites in lipase which, seems to be a determinant factor 
in the inhibitory effects. It can be speculated that silibinin(A) inhibits 
pancreatic lipase activity mainly through the blockade of the confor-
mational changes that expose the catalytic centre when lipase contacts 
the oil–water interface. Conversely, GSSG activity on pancreatic lipase 
seems to be more related to the occupation of the catalytic centre, 
causing a kind of hindrance for triglycerides turnover. Conformational 
changes upon adsorption at the oil–water interface proceed and the 
layer loses elasticity as discussed in the previous section. 
This agrees with results from virtual screening. Silibinin(A) was able 
to interact with the amino acid trp252, which has been described as a 
crucial factor for the stabilization of the lid with the catalytic centre of 
pancreatic lipase. In addition, the virtual screening location of silibinin 
(A) suggests that it protrudes from the enzyme surface, so it could more 
easily contact the oil–water interface hence preventing lipolysis. He and 
co-workers have reported that the aromatic rings of polyphenol com-
pounds interact hydrophobically with pancreatic lipase amino acids, 
phenylalanine and tyrosine (He, Lv, & Yao, 2006). This observation is in 
line with the predicted interactions between silibinin(A) and Phe77 and 
Trp252. Besides, another hydrophobic interaction was predicted be-
tween the hydroxyl groups of polyphenolic compounds and polar groups 
of pancreatic lipase (Martinez-Gonzalez et al., 2017). Both hydrophobic 
interactions will change the lipase conformational stability, resulting in 
a strong inhibitory activity. 
Furthermore, Martinez-González and co-workers described that 
Quercetin, an effective lipase inhibitor, presented more polar in-
teractions than others polyphenolic compounds on pancreatic lipase. 
This flavonoid has a high affinity towards proteins due to its structural 
characteristics. It is known that the number of rings and the free hy-
droxyl groups are associated with the ability of these compounds to 
interact with proteins (Martinez-Gonzalez et al., 2017). For these rea-
sons, the polyphenols from different origins have been studied to inhibit 
Fig. 4. The time dependence of the fatty acid release (%) from olive O/W emulsions stabilized with Tween 20, after adding lipase and bile salts (T = 37 ◦C). At least 
three measures were made. AUC of lipase, lipase-Orlistat, lipase-GSSG, lipase-Silibinin(A). Lipase (1.6 g/l), Orlistat (0.22 g/l), GSSG (0.88 g/l) or Silibinin(A) (0.88 g/ 
l) were used at final concentrations. 
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the lipase in previous papers (Gondoin, Grussu, Stewart, & McDougall, 
2010; Li et al., 2018; Vinodhini & Rajeswari, 2019). We find similarities 
between quercetin and silibinin(A) molecular structures, since the 
structure of quercetin is contained in site of silibinin(A) molecule 
(Fig. 1), which may explain the similar mechanism of action of quercetin 
and silibinin(A). It was also reported that Quercetin bound close to the 
active site of pancreatic lipase (Martinez-Gonzalez et al., 2017). The 
bind between lipase/Silibinin(A) would change the lipase structure, 
hence inhibiting its action. In the case of GSSG, the interfacial results 
correlate with the less inhibition capacity obtained as compared with 
orlistat. GSSG clearly inhibits lipase activity, preventing FFA release 
(Fig. 4). The presence of hydroxyl groups could interact with the active 
centre of pancreatic lipase. Furthermore, the antioxidant properties of 
this molecule could interfere and encourage the lipase inhibition. 
According to the Virtual Screening, the main differences found in the 
interaction of the different inhibitors with lipase rely in the different 
interaction encountered with hydrophobic amino acids. The inhibition 
of lipase through hydrogen bounds in Gly76, Asp79, Arg256 and His151 
for orlistat and GSSG were similar, although the interactions were hy-
drophobic in the case of silibinin (Ile78, Ala178 and Ala280) 
(Table Supplementary 2). There are some amino acids in common for 
both inhibitors like (Phe77 and Phe215) but the interactions are 
hydrogen bound for GSSG and hydrophobic for silibinin(A). Thus, orli-
stat, tributyrin and silibinin(A) bind to hydrophobic amino acid Leu, 
bind more strongly to Phe77 via hydrogen bonds (Fig. 2). Hence, these 
bindings might well reduce the hydrophobic sites in the complex, hence 
interfacial activity and ultimately lipolysis. Conversely, orlistat and 
GSSG bind to Lys, which is buried inside lipase, via salt bond (Fig. 2). 
This type of interaction possibly alters conformational stability of 
pancreatic lipase, hence reducing the elasticity of adsorbed lipase layer. 
Moreover, a conclusion from this study is that the lipolytic action is 
directly related to interaction with hydrophobic sites. Compounds that 
interact via hydrogen bonds, such as silibinin(A) and orlistat, reduce the 
hydrophobicity of lipase, providing an improved inhibition of lipolysis 
in vitro. 
4. Conclusion 
In summary, combination of in silico and in vitro studies of allow the 
rational investigation of new lipase inhibitors. The inhibitory potential 
is quantified for emulsified systems while interfacial and in silico studies 
allow further interpretation of the findings at the molecular level. The 
interaction with hydrophobic sites in lipase seems to be a crucial factor 
determining the lipolytic action of lipase. This is quantified by 
measuring the amount of free fatty acids released upon in-vitro lipolysis, 
being more efficient the inhibition when interaction with hydrophobic 
amino acids occurs. This is possibly related to the reduced interfacial 
activity of the complex when hydrophobic interaction occurs (silibinin 
(A) and orlistat) and with denaturation of lipase when interaction with 
polar amino acids buried in the molecule occur (GSSG). Results from this 
study confirmed that both GSSG and silibinin(A) are effective pancreatic 
lipase inhibitors, with potential as complements to dietary therapy for 
the treatment of obesity. Further in vivo and clinical studies are neces-
sary to verify the effectiveness of these compounds for its use in humans, 
since, in addition to being natural compounds, their safety regarding 
human administration has already been demonstrated (Wah Kheong, 
Nik Mustapha, & Mahadeva, 2017). 
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